Comparison and selection of statistical methods in data analysis of HPV vaccine clinical trials

Yiwen Duan

doi:10.54097/630hae10

Authors

Yiwen Duan

DOI:

https://doi.org/10.54097/630hae10

Keywords:

Vaccine efficacy, security, immune persistence, Human papillomavirus (HPV)

Abstract

Human papillomavirus (HPV) is a global health problem that cannot be ignored, and it is strongly associated with many types of cancer. The analysis of HPV vaccine clinical trial data is critical to accurately assess key indicators of vaccine efficacy, safety, and immune persistence. Statistical methods are indispensable tools in this field of research. In this paper, we systematically review the commonly used statistical methods in the analysis of HPV vaccine clinical trial data, including descriptive statistics, hypothesis testing, survival analysis, regression analysis, etc., and discuss the characteristics of each method, its applicability scenarios, and its application in HPV vaccine research. Through comparative analysis, this paper summarizes the basis for selecting different statistical methods, which provides a reference for researchers to choose reasonable statistical methods when facing complex data types and diverse research objectives. This, in turn, facilitates the research and development, scientific evaluation, and wide-spread dissemination of HPV vaccines, thereby advancing global public health towards a new stage of development.

Downloads

Download data is not yet available.

References

[1] Chand, T., Dubey, A.K., Misra, G. 2025. Unraveling HPV-associated cancer complexity: From molecular insights to innovative therapies. Heliyon 11:e42437.

[2] Chen, W. 2025. Problems Needing Attention in the Statistical Processing of Data in Papers [J]. The Journal of Traditional Chinese Orthopedics and Traumatology37(02): 3.

[3] Das, D., Saikia, H., Bora, D., Bhattacharjee, D., Das, J. 2022. A survival analysis approach for identifying the risk factors in time to recovery of COVID-19 patients using Cox proportional hazard model. Decision Analytics Journal 5:100137.

[4] Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., Bray, F. 2021. Cancer statistics for the year 2020: An overview. International Journal of Cancer.

[5] Gore, M., Kabekkodu, S.P., Chakrabarty, S. 2025. Exploring the metabolic alterations in cervical cancer induced by HPV oncoproteins: From mechanisms to therapeutic targets. BBA-Reviews on Cancer 1880:189292.

[6] Jia, X., Hu, S., Kuang, X., Qiao, Y. 2025. Long-term protective efficacy of the Escherichia coli - produced HPV-16/18 bivalent human papillomavirus vaccine in women vaccinated at 18–45 years: A 9-year follow-up study. Infectious Medicine 4:100164.

[7] Liu, Y., Chen, D., Zhao, L., Zhang et al. 2025. Stability study of recombinant 9-valent human papillomavirus vaccine based on Escherichia coli expression system. Human Vaccines & Immunotherapeutics 21(1):2455807.

[8] Nealon, J., Mefsin, Y.M., McMenamin, M.E., Ainslie, K.E.C., Cowling, B.J. 2024. Reported effectiveness of COVID-19 monovalent booster vaccines and hybrid immunity against mild and severe Omicron disease in adults: A systematic review and meta-regression analysis. Vaccine X 17:100451.

[9] Sung H, Ferlay J, Siegel RL, et al. 2021. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin 71(3):209-249.

[10] Sierra, M.S., Carvajal, L.J., Dull, P., Herrero, R., Schussler, J., Hildesheim, A., Schiller, et al. 2025. Human papillomavirus type 16 and 18 viral clearance and progression to precancer among women aged 18–25 years enrolled in the Costa Rica HPV prophylactic vaccine trial (CVT). Vaccine 50:126841.

[11] Wang, R., Pan, W., Jin, L., Huang, W., Li, Y., Wu, D., Gao, C., Ma, D., Liao, S. 2020. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Letters 471:88–102.

[12] Xing, R. Y. 2022. Clinical statistical evaluation of HPV vaccine safety Master's thesis, Guilin University of Electronic Technology.